Cargando…
Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives
Any type of sexual dysfunction is an important problem in half of the patients with depressive disorder. On the other hand, one to a quarter of people without any depressive disorder experience sexual dysfunction. Antidepressant agents can lead to all types of sexual side effects including arousal,...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182464/ https://www.ncbi.nlm.nih.gov/pubmed/32368066 http://dx.doi.org/10.2147/NDT.S185757 |
_version_ | 1783526246585466880 |
---|---|
author | Atmaca, Murad |
author_facet | Atmaca, Murad |
author_sort | Atmaca, Murad |
collection | PubMed |
description | Any type of sexual dysfunction is an important problem in half of the patients with depressive disorder. On the other hand, one to a quarter of people without any depressive disorder experience sexual dysfunction. Antidepressant agents can lead to all types of sexual side effects including arousal, libido, orgasm and ejaculation problems. Selective serotonin reuptake inhibitors (SSRIs) are a widely used class of drugs which are prescribed for the treatment of a variety of disorders, including major depressive disorder, obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder, generalized anxiety disorder, and impulse control disorders. It has been reported that one in eight people have utilized one of the SSRIs in the past 10 years. Some studies reported up to 80% of SSRI-induced sexual side effects. Management of SSRI-induced sexual dysfunction seems to be complex and hard. In this paper, SSRI-induced sexual dysfunction and new perspectives in the management of this problem were reviewed. |
format | Online Article Text |
id | pubmed-7182464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-71824642020-05-04 Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives Atmaca, Murad Neuropsychiatr Dis Treat Review Any type of sexual dysfunction is an important problem in half of the patients with depressive disorder. On the other hand, one to a quarter of people without any depressive disorder experience sexual dysfunction. Antidepressant agents can lead to all types of sexual side effects including arousal, libido, orgasm and ejaculation problems. Selective serotonin reuptake inhibitors (SSRIs) are a widely used class of drugs which are prescribed for the treatment of a variety of disorders, including major depressive disorder, obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder, generalized anxiety disorder, and impulse control disorders. It has been reported that one in eight people have utilized one of the SSRIs in the past 10 years. Some studies reported up to 80% of SSRI-induced sexual side effects. Management of SSRI-induced sexual dysfunction seems to be complex and hard. In this paper, SSRI-induced sexual dysfunction and new perspectives in the management of this problem were reviewed. Dove 2020-04-20 /pmc/articles/PMC7182464/ /pubmed/32368066 http://dx.doi.org/10.2147/NDT.S185757 Text en © 2020 Atmaca. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Atmaca, Murad Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives |
title | Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives |
title_full | Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives |
title_fullStr | Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives |
title_full_unstemmed | Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives |
title_short | Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives |
title_sort | selective serotonin reuptake inhibitor-induced sexual dysfunction: current management perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182464/ https://www.ncbi.nlm.nih.gov/pubmed/32368066 http://dx.doi.org/10.2147/NDT.S185757 |
work_keys_str_mv | AT atmacamurad selectiveserotoninreuptakeinhibitorinducedsexualdysfunctioncurrentmanagementperspectives |